Clinical evaluation of Luhong compound in improving myocardial fibrosis in patients with chronic heart failure

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000037368

Enrollment

Unknown

Registered

2020-08-28

Start date

2020-12-01

Completion date

Unknown

Last updated

2020-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial fibrosis in patients with chronic heart failure

Interventions

experimental group:On the basis of standardized treatment of chronic heart failure, LuHong formula was added

control group:Placebo: the appearance of comfort granules was exactly the same as the test drug. The drug ingredients containing the formulation agent and less than 5% of the above prescriptions are p

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) According to the diagnostic criteria of stage C of heart failure; (2) The age ranged from 18 to 80 years old; (3) The clinical observation data were collected completely; (4) The subjects agreed to test the relevant clinical indicators.

Exclusion criteria

Exclusion criteria: (1) Patients with definite multi system infection, tumor, connective tissue disease, autoimmune disease, recent operation or trauma; (2) Moderate to severe dementia or mental illness can not cooperate with follow-up investigation; (3) Pregnant and lactating women; (4) The patients died in the acute phase.

Design outcomes

Primary

Measure	Time frame
P III NP, PICP, Serum levels of type I and type III collagen;	—

Countries

China

Contacts

Public ContactYang Tao

Shuguang Hospital Affiliated to Shanghai University of traditional Chinese Medicine

yangtao8579@163.com+86 13917577668

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026